These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sargramostim (GM-CSF) for induction of remission in Crohn's disease. Roth L; Macdonald JK; McDonald JW; Chande N Cochrane Database Syst Rev; 2011 Nov; (11):CD008538. PubMed ID: 22071853 [TBL] [Abstract][Full Text] [Related]
6. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Korzenik JR; Dieckgraefe BK Aliment Pharmacol Ther; 2005 Feb; 21(4):391-400. PubMed ID: 15709989 [TBL] [Abstract][Full Text] [Related]
10. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Dieckgraefe BK; Korzenik JR Lancet; 2002 Nov; 360(9344):1478-80. PubMed ID: 12433518 [TBL] [Abstract][Full Text] [Related]
11. Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells. Mannon PJ; Leon F; Fuss IJ; Walter BA; Begnami M; Quezado M; Yang Z; Yi C; Groden C; Friend J; Hornung RL; Brown M; Gurprasad S; Kelsall B; Strober W Clin Exp Immunol; 2009 Mar; 155(3):447-56. PubMed ID: 19094118 [TBL] [Abstract][Full Text] [Related]
12. Cytokine refacing effect reduces granulocyte macrophage colony-stimulating factor susceptibility to antibody neutralization. Heinzelman P; Carlson SJ; Cox GN Protein Eng Des Sel; 2015 Oct; 28(10):461-6. PubMed ID: 25855658 [TBL] [Abstract][Full Text] [Related]
13. A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. Chuang LS; Villaverde N; Hui KY; Mortha A; Rahman A; Levine AP; Haritunians T; Evelyn Ng SM; Zhang W; Hsu NY; Facey JA; Luong T; Fernandez-Hernandez H; Li D; Rivas M; Schiff ER; Gusev A; Schumm LP; Bowen BM; Sharma Y; Ning K; Remark R; Gnjatic S; Legnani P; George J; Sands BE; Stempak JM; Datta LW; Lipka S; Katz S; Cheifetz AS; Barzilai N; Pontikos N; Abraham C; Dubinsky MJ; Targan S; Taylor K; Rotter JI; Scherl EJ; Desnick RJ; Abreu MT; Zhao H; Atzmon G; Pe'er I; Kugathasan S; Hakonarson H; McCauley JL; Lencz T; Darvasi A; Plagnol V; Silverberg MS; Muise AM; Brant SR; Daly MJ; Segal AW; Duerr RH; Merad M; McGovern DP; Peter I; Cho JH Gastroenterology; 2016 Oct; 151(4):710-723.e2. PubMed ID: 27377463 [TBL] [Abstract][Full Text] [Related]
14. Crohn's disease: an immunodeficiency? Folwaczny C; Glas J; Török HP Eur J Gastroenterol Hepatol; 2003 Jun; 15(6):621-6. PubMed ID: 12840672 [TBL] [Abstract][Full Text] [Related]
15. New treatment options in the management of IBD - focus on colony stimulating factors. Barahona-Garrido J; Yamamoto-Furusho JK Biologics; 2008 Sep; 2(3):501-4. PubMed ID: 19707380 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human granulocyte-macrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn's disease. Magno P; Jiménez CE; Ortiz Z; Torres EA P R Health Sci J; 2010 Mar; 29(1):60-5. PubMed ID: 20222336 [TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways. Brosbøl-Ravnborg A; Hvas CL; Agnholt J; Dahlerup JF; Vind I; Till A; Rosenstiel P; Höllsberg P Clin Exp Immunol; 2009 Mar; 155(3):487-95. PubMed ID: 19094116 [TBL] [Abstract][Full Text] [Related]